Identifying Therapeutic Vulnerabilities of Pediatric Cancers with ATRX Deficiency

Pediatric malignant glioma is the deadliest pediatric cancer. Since about a third have ATRX deficiency and alternative lengthening of telomeres (ALT), Dr. Cole’s recent laboratory efforts have been to target these vulnerabilities. In collaboration with the Children’s Brain Tumor Tissue Consortium, Dr. Cole has created reagents to accomplish this, including an integrated set of 70 sequenced tumors with corresponding cell lines, patient-derived xenografts, and a tissue microarray.

Our Collaborators